Theialife Secured FDA Alignment for Myopia Study
The company cleared a Type C regulatory meeting to advance its pivotal Phase 3 program for pediatric myopia.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do you trust that new pharmaceutical treatments will solve the root causes of childhood conditions?
Theialife has reached an agreement with the FDA on the design of a pivotal Phase 3 clinical program for ND10, an investigational oral therapy for progressive pediatric myopia. The research-stage program will evaluate the drug's effect on myopia progression.
Why it matters
The meeting provides regulatory clarity for Theialife to proceed with its development timeline for a new pediatric myopia treatment. Clinical alignment is a prerequisite for moving the candidate into late-stage testing.
The planned clinical program includes two trials, ORBIS 1 and ORBIS 2, which will randomize participants to receive ND10 extended-release capsules or a placebo. All subjects will wear single-vision corrective lenses while researchers perform interim efficacy analyses.
The players
Theialife
A pharmaceutical company developing novel therapies for vision health, currently focused on its lead pediatric myopia candidate, ND10.
Rupa Wong
A clinical lead at the Honolulu Eye Clinic responsible for overseeing the ORBIS 1 and ORBIS 2 trial program.
The details
The program utilizes an extended-release capsule formulation designed for daily administration. Participants across both trials will undergo longitudinal monitoring to determine if ND10 can slow the axial lengthening of the eye, which is the physical cause of myopia progression. The study protocol incorporates an interim efficacy check and follow-up periods to measure the durability of the treatment effect compared to a control group using standard corrective lenses.
Timeline
October 7, 2026: Theialife completed the Type C meeting with the FDA.
First half of 2027: The company plans to initiate the two pivotal studies.
The Tech Race
The company is advancing toward its pivotal Phase 3 milestone following the regulatory feedback gained through the FDA Type C meeting process. This regulatory consensus serves as the critical checkpoint for Theialife as it competes to establish a new standard for myopia intervention.
This development marks a research milestone rather than a product launch, meaning ND10 remains unavailable to patients. Should the upcoming trials succeed, the therapy would offer a new pharmaceutical option for children currently reliant on standard corrective lenses to manage myopia progression.
The takeaway
Theialife has achieved the regulatory agreement required to move its myopia therapy into late-stage clinical evaluation. Observers should monitor the company for updates regarding its Series A financing, which is the next definitive hurdle for starting the ORBIS trials.
What happens next
The initiation of the two pivotal studies in the first half of 2027 remains contingent upon receiving IND acceptance and closing a successful Series A financing round.
Further reading
For more on the current landscape of ocular drug development, visit Biotech.
More information
Review the clinical roadmap and company mission on the Theialife company information portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that new pharmaceutical treatments will solve the root causes of childhood conditions?
